Abstract
Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across KIT/PDGFRA mutation subgroups.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6333-6342 |
| Number of pages | 10 |
| Journal | Clinical Cancer Research |
| Volume | 27 |
| Issue number | 23 |
| DOIs | |
| State | Published - Dec 1 2021 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. / Bauer, Sebastian; Heinrich, Michael C.; George, Suzanne; Zalcberg, John R.; Serrano, Cesar; Gelderblom, Hans; Jones, Robin L.; Attia, Steven; D'Amato, Gina; Chi, Ping; Reichardt, Peter; Meade, Julie; Su, Ying; Ruiz-Soto, Rodrigo; Blay, Jean Yves; Mehren, Margaret Von; Sch€offski, Patrick.
In: Clinical Cancer Research, Vol. 27, No. 23, 01.12.2021, p. 6333-6342.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
AU - Bauer, Sebastian
AU - Heinrich, Michael C.
AU - George, Suzanne
AU - Zalcberg, John R.
AU - Serrano, Cesar
AU - Gelderblom, Hans
AU - Jones, Robin L.
AU - Attia, Steven
AU - D'Amato, Gina
AU - Chi, Ping
AU - Reichardt, Peter
AU - Meade, Julie
AU - Su, Ying
AU - Ruiz-Soto, Rodrigo
AU - Blay, Jean Yves
AU - Mehren, Margaret Von
AU - Sch€offski, Patrick
N1 - Funding Information: S. Bauer reports personal fees from Deciphera Pharmaceuticals, Roche, Exelixis, Plexxikon, and Daichii Sankyo; grants from Incyte; grants and personal fees from Blueprint Medicines and Novartis; personal fees and other support from Bayer and Pharmamar; and other support from Pfizer during the conduct of the study. S. Bauer also reports personal fees from GSK outside the submitted work. M.C. Heinrich reports personal fees from Deciphera Pharmaceuticals, Theseus, and Blueprint Medicines during the conduct of the study. M.C. Heinrich also reports personal fees and other support from MolecularMD, as well as personal fees from Novartis outside the submitted work; in addition, M.C. Heinrich has a patent for Imatinib treatment of GIST issued, licensed, and with royalties paid from Novartis. S. George reports other support from Abbott Laboratories, Kayothera, Daiichi Sankyo, Springworks, UpToDate, ResearchToPractice, MORE Health, Grand Rounds, and NCCN; personal fees and other support from Deciphera Pharmaceuticals and Blueprint Medicines; personal fees from Eli Lilly; and grants and other support from Eisai and Merck outside the submitted work. In addition, S. George is the Vice Chair Alliance for Clinical Trials in Oncology and Vice President of Alliance Foundation. J.R. Zalcberg reports other support from Deciphera Pharmaceuticals during the conduct of the study; J.R. Zalcberg also reports grants from MSD, as well as personal fees from MSD, STA, Merck, Targovax, Halozyme, CEND, and Gilead outside the submitted work. In addition, J.R. Zalcberg owns stock in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, Biomarin, Opthea, Armarin, Concert Pharmaceuticals, Frequency Therapeutics, Global Blood Therapeutics, Gilead, Madrigal Pharmaceuticals, Sangamo Biosciences, Acceleron Pharmaceuticals, Zogenix, Myovant Sciences, Orphazyme, Moderna Therapeutics, Novo Nordisk, Novavax, and TWST. C. Serrano reports grants and personal fees from Deciphera Pharmaceuticals; grants and non-financial support from Pfizer and Bayer; personal fees and non-financial support from Blueprint; personal fees from Immunicum; and non-financial support from Novartis, Lilly, and Pharmamar during the conduct of the study. H. Gelderblom reports institutional funding from Daiichi Sankyo, Novartis, Deciphera Pharmaceuticals, Debio, and Boehringer Ingelheim. R.L. Jones reports other support from Deciphera Pharmaceuticals during the conduct of the study, as well as personal fees from Athenex, Eisai, Blueprint, Deciphera Pharmaceuticals, Pharmamar, Tracon, Spring-works, and UpToDate outside the submitted work; in addition, R.L. Jones has a patent for Biomarker pending. S. Attia reports grants from Deciphera Pharmaceuticals during the conduct of the study, as well as grants from AB Science, Tracon, GSK, BTG, Bayer, Novartis, Lilly, Immune Design, Karyopharm, Epizyme, Blueprint, Genmab, CBA, DTRF, Merck, Philogen, Gradilis, Takeda, Incyte, Springworks, Adaptimmune, Advenchen, PTC Therapeutics, Bavarian Nordic, and FORMA Therapeutics outside the submitted work. G. D’Amato reports other support from Deciphera Pharmaceuticals, Blueprint, Daiichi Sankyo, and Epizyme outside the submitted work. P. Chi reports grants, personal fees and non-financial support from Deciphera Pharmaceuticals during the conduct of the study; P. Chi also reports personal fees from Exelixis and Zai Lab, as well as grants from NingboNewBay and Pfizer outside the submitted work. P. Reichardt reports personal fees from Bayer, Clinigen, BMS, Roche, MSD, Deciphera Pharmaceuticals, Novartis, Pfizer, Pharmamar, Lilly, Amgen, and Blueprint outside the submitted work. J. Meade reports personal fees from Deciphera Pharmaceuticals during the conduct of the study, as well as other support from Deciphera Pharmaceuticals outside the submitted work; in addition, J. Meade is an employee of Deciphera Pharmaceuticals. Y. Su reports employment at Deciphera Pharmaceuticals. R. Ruiz-Soto reports other support from Deciphera Pharmaceuticals during the conduct of the study, as well as other support from Deciphera Pharmaceuticals outside the submitted work. J.-Y. Blay reports grants from Deciphera Pharmaceuticals during the conduct of the study; J.-Y. Blay also reports grants and personal fees from Deciphera Pharmaceuticals, Blueprint, and Eisai, as well as grants from Bayer outside the submitted work. M. von Mehren reports personal fees and other support from Deciphera Pharmaceuticals, as well as personal fees from Publisher Copyright: © 2021 American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across KIT/PDGFRA mutation subgroups.
AB - Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across KIT/PDGFRA mutation subgroups.
UR - http://www.scopus.com/inward/record.url?scp=85120457202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120457202&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-21-1864
DO - 10.1158/1078-0432.CCR-21-1864
M3 - Article
C2 - 34503977
AN - SCOPUS:85120457202
VL - 27
SP - 6333
EP - 6342
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 23
ER -